Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Cras viverra rhoncus metu
$77.00Add to cartAenean ut commodo justo. Fusce accumsan erat ut purus mollis, quis fermentum magna luctus. Morbi pulvinar augue lorem, quis molestie ipsum dictum non. Donec malesuada fermentum ex non hendrerit. Sed tempor viverra arcu a ultrices. Suspendisse non malesuada massa. Praesent imperdiet rhoncus nunc, vel fringilla enim lacinia quis
-
Quick View
Nunc tempus facilisis
$87.00Add to cartFusce ullamcorper dapibus eleifend. Nullam ornare pulvinar lacinia. Nunc tempus facilisis ullamcorper. Nam sit amet suscipit risus, ut ultricies felis. Vivamus a finibus nisi. Sed quam sem, accumsan eget tristique sit amet, suscipit sit amet augue. Duis dolor dui, sagittis at faucibus ac, varius et sapien.
-
Quick View
Phasellus molestie id mi sit amet
$66.00Add to cartMorbi mattis ipsum sem, in gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat.
-
Quick View
Fusce ullamcorper dapibus
Original price was: $55.00.$41.00Current price is: $41.00.Add to cartVestibulum quis augue sem. Curabitur non vehicula elit, et cursus tortor. Quisque placerat velit nec nulla sodales, porttitor mattis tortor porta. Praesent gravida leo nibh, vel semper nulla lobortis vel. Donec nisl velit, iaculis ac dolor eget, blandit elementum urna. Mauris pellentesque posuere pellentesque. Nunc fermentum purus a consequat fringilla. Donec finibus suscipit erat in pharetra
Reviews
There are no reviews yet.